FDA approves oral combination of Dacogen and Cedazuridine for patients with myelodysplastic syndromes

Summary: The Food and Drug Administration (FDA) recently announced a new approved treatment option, Inqovi, for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is an evolution from the existing treatment, decitabine (Dacogen), because it can be administered by month instead of IV.

Dr. Dan’s Takeaway: Inqovi has similar effectiveness and safety to IV decitabine (Dacogen), but it can be taken as a pill. It is therefore more convenient for patients, who will no longer have to go into the hospital for five consecutive days of IV Dacogen infusions every month.

Resources:

https://www.curetoday.com/view/fda-approves-oral-combination-of-dacogen-and-cedazuridine-for-patients-with-myelodysplastic-syndromes

Deskside with Dr. Dan

“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

- Dan Platt, M.D.
Chief Medical Officer